Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Colorado: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 26 | 1,245 | 46% |
| 2020 | 24 | 1,094 | 48% |
| 2021 | 22 | 1,201 | 50% |
| 2022 | 32 | 1,185 | 53% |
| 2023 | 27 | 1,205 | 55% |
| 2024 | 24 | 1,147 | 57% |
| 2025 from claims | – | 1,162 1,066–1,229 | 57% |
| 2026 forecast | – | 1,207 1,062–1,393 | 56% |
| 2027 forecast | – | 1,225 1,047–1,460 | 56% |
| 2028 forecast | – | 1,244 1,038–1,523 | 57% |
| 2029 forecast | – | 1,263 1,032–1,584 | 57% |
| 2030 forecast | – | 1,282 1,027–1,643 | 57% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 61% of the cases CMS names in Colorado; 16 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 71% inpatient hospital, 28% hospital outpatient, 1% surgery center.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 77 | 3,603−4%/yr | −4%/yr | 1.0 | 0% | 4,270 in 2030+2.9%/yr |
| Arizona | 36 | 1,337+2.4%/yr | +2.4%/yr | 1.7 | 6% | 1,730 in 2030+4.4%/yr |
| Washington | 12 | 886−6.9%/yr | −6.9%/yr | 1.1 | 11% | 890 in 20300%/yr |
| Oregon | 11 | 615−5.6%/yr | −5.6%/yr | 1.4 | 25% | 690 in 2030+2%/yr |
| Utah | 9 | 439−3.4%/yr | −3.4%/yr | 1.9 | 17% | 560 in 2030+4.1%/yr |
| Nevada | 3 | 378−6.4%/yr | −6.4%/yr | 1.3 | 0% | 370 in 2030−0.3%/yr |
| Idaho | 8 | 341−3.9%/yr | −3.9%/yr | 1.6 | 0% | 450 in 2030+4.8%/yr |
| Montana | 4 | 238−0.9%/yr | −0.9%/yr | 1.2 | 0% | 270 in 2030+2.1%/yr |
| Alaska | 5 | 221+8.1%/yr | +8.1%/yr | 1.8 | 0% | 400 in 2030+10%/yr |
| New Mexico | 2 | 123−6.5%/yr | −6.5%/yr | 0.5 | 0% | 250 in 2030+13%/yr |
| Wyoming | 2 | 111−8.1%/yr | −8.1%/yr | 1.0 | 0% | 160 in 2030+6.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 67 | 2,336−3.9%/yr | −3.9%/yr | 4.61.7× | 1% | 2,600 in 2030+1.8%/yr |
| Decompression & minimally invasive spine | 51 | 2,105−5.5%/yr | −5.5%/yr | 4.21.3× | 5% | 2,480 in 2030+2.7%/yr |
| Kyphoplasty & vertebroplasty | 0 | 538−5.5%/yr | −5.5%/yr | 1.11.2× | 18% | 560 in 2030+0.6%/yr |
| SI joint fusion | 9 | 330+20%/yr | +20%/yr | 0.63.1× | 11% | 570 in 2030+9.4%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Colorado · Every state · Compare with California
Medtronic leads with 49% of company spending on these surgeons in 2025, −14 pts on 2024.
In 2025, 15 companies reported engagement with Colorado’s surgeons worth $377K in consulting, speaking, meals and travel tied to these products, about $16K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.